- Patients with long QT syndrome (LQTS) face potential threats from COVID-19 vaccination. Fever is one of the issues that is not uncommon after vaccination, and it usually takes place within 2 days. In particular, patients with type 2 LQTS based on trafficking-deficient variants are probably vulnerable to arrhythmogenicity under febrile conditions. Furthermore, myocarditis is one of the rare complications that is possibly associated with acquired QT prolongation and puts patients with LQTS at risk of life-threatening arrhythmia.
- Effects of the COVID-19 pandemic on cardiac rhythm management (CRM) services remain poorly quantified.
- Coronavirus disease 2019 (COVID-19) has encompassed the globe since it was first observed just under 2 years ago. Although the disease is predominantly a respiratory illness, there have been observed complications throughout the various organ systems. Namely, cardiovascular complications, and, more specifically, arrhythmic complications have been described throughout the pandemic in patients with COVID-19. Management of atrial arrhythmias, ventricular arrhythmias, and bradyarrhythmias in patients with COVID-19 infection has been largely guided by our prior experience in the management of these arrhythmias in similar patient populations without infection.
- First reports from the initial epicenter of the coronavirus disease 2019 (COVID-19) outbreak in Wuhan, China included case series of rapid clinical deterioration of seemingly healthy individuals.1,2 Based on a cohort of 138 Chinese patients, 16.7% of patients with COVID-19 suffered from unspecified arrhythmias despite cardiac biomarkers being within normal range. In patients admitted to the intensive care unit (ICU), arrhythmias was reported in 44.4% of the patients. But how diagnosis of arrhythmias were made was not clearly specified.
- The tools of digital health are facilitating a much-needed paradigm shift to a more patient-centric health care delivery system, yet our health care infrastructure is firmly rooted in a 20th-century model that was not designed to receive medical data from outside the traditional medical environment. COVID-19 has accelerated this adoption and illustrated the challenges that lie ahead as we make this shift. The diverse ecosystem of digital health tools share 1 feature in common: they generate data that must be processed, triaged, acted upon, and incorporated into the longitudinal electronic health record.
- During the COVID-19 pandemic, attempts to conserve resources and limit virus spread have resulted in delay of nonemergent procedures across all medical specialties, including cardiac electrophysiology (EP). Many patients have delayed care and continue to express concerns about potential nosocomial spread of coronavirus.
- Observational studies have suggested increased arrhythmic and cardiovascular risk with the combination use of hydroxychloroquine (HCQ) and azithromycin in patients with coronavirus disease 2019 (COVID-19).
- Our world is faced with a global pandemic that threatens to overwhelm many national health care systems for a prolonged period. Consequently, the elective long-term cardiac implantable electronic device (CIED) management of millions of patients is potentially compromised, raising the likelihood of patients experiencing major adverse events owing to loss of CIED therapy. This review gives practical guidance to health care providers to help promptly recognize the requirement for expert consultation for urgent interrogation and/or surgery in CIED patients.
- During the COVID-19 pandemic and with worldwide medical colleagues, the electrophysiology (EP) community has encountered challenges that are unique in our collective consciousness. Just a few short weeks ago, we focused on accessory pathway potentials, or local abnormal ventricular activation, or pulmonary vein potentials, and/or those from the His bundle. Now, our expanded focus on “potentials” includes arenas outside the EP laboratory as we expand our partnership with procedure centers, hospitals, regions, nations, and the world.